Captain Keryx Beams Up Sales

8/8/17

Keryx Biopharmaceuticals (KERX) is a $760-million market cap biopharmaceutical company focused on development and commercialization of innovative medicines for people with renal disease. KERX's first approved medicine, AURYXIA (ferric citrate), was approved in 2014 for the treatment of anemia and hyperphosphatemia associated with kidney disease in patients requiring dialysis. Recent company guidance was encouraging, resulting in full-year 2017 AURYXIA sales estimates raised from $62 to $66 million. Greg Madison, KERX CEO, stated, “This demand was largely driven by solid execution across our entire field team, which increased both breadth and depth of prescribing among physicians. With this momentum, we have increased our annual net Auryxia product sales guidance, reflecting improved confidence in our ability to bring this medicine to a greater number of people with chronic kidney disease (CKD) on dialysis this year.”

READ FULL ARTICLE HERE

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.